Find Cicletanine manufacturers, exporters & distributors on PharmaCompass

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 1 USDMF, 1 Listed Suppliers

2 API Suppliers
1 USDMF
1 Listed Suppliers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Cycletanide, 89943-82-8, Bn-1270, Win 90,000, Win-90000, Chg7qc509w

Molecular Formula

C₁₄H₁₂ClNO₂

Molecular Weight

261.70 g/mol

InChI Key

CVKNDPRBJVBDSS-UHFFFAOYSA-N

FDA UNII

CHG7QC509W

Cicletanine is a dihydropyridine derivative with diuretic and antihypertensive activity. Cicletanine exerts thiazide-like diuretic activity. In addition, this agent inhibits protein kinase C (PKC) and is able to reverse vasoconstriction through the inhibition of PKC-mediated inhibition of Na/K-ATPase phosphorylation.

1 2D Structure

Cicletanine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-(4-chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol

2.1.2 InChI

InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3

2.1.3 InChI Key

CVKNDPRBJVBDSS-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=NC=C2C(OCC2=C1O)C3=CC=C(C=C3)Cl

2.2 Other Identifiers

2.2.1 UNII

CHG7QC509W

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 1,3-dihydro-6-methyl-7-hydroxy-3-(4-chlorophenyl)furo(3,4-d)pyridine

2. Bn 1270

3. Bn-1270

4. Cicletanide

5. Cicletanine Hydrochloride

6. Cycletanide

7. Justar

8. Tenstaten

2.3.2 Depositor-Supplied Synonyms

1. Cycletanide

2. 89943-82-8

3. Bn-1270

4. Win 90,000

5. Win-90000

6. Chg7qc509w

7. 3-(4-chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol

8. Tenstaten

9. Justar

10. (+/-)bn-1270

11. Cicletanina

12. Cicletaninum

13. Cicletaninum [latin]

14. (+/-)-cicletanine

15. Cicletanina [spanish]

16. Unii-chg7qc509w

17. Cicletanine [usan:inn:ban]

18. Cicletanine [mi]

19. Cicletanine [inn]

20. Cicletanine (usan/inn)

21. Cicletanine [usan]

22. (+-)-bn-1270

23. Cicletanine [mart.]

24. Schembl49794

25. Cicletanine [who-dd]

26. Chembl191886

27. (r)-(-)-cicletanine

28. Dtxsid70868972

29. Chebi:135078

30. (+-)-3-(p-chlorophenyl)-1,3-dihydro-6-methylfuro(3,4-c)pyridin-7-ol

31. Akos022665941

32. Db12766

33. Bn-50417

34. Bn-50418

35. Ds-017342

36. D03487

37. (+/-)-bn-1270

38. Q5119443

39. 3-(4-chlorophenyl)-6-methyl-1h,3h-furo[3,4-c]pyridin-7-ol

40. Furo(3,4-c)pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (+-)-

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₁₄H₁₂ClNO₂
Molecular Weight	261.70 g/mol
XLogP3	2.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	1
Exact Mass	261.0556563 g/mol
Monoisotopic Mass	261.0556563 g/mol
Topological Polar Surface Area	42.4 Å²
Heavy Atom Count	18
Formal Charge	0
Complexity	294
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Anti-Arrhythmia Agents

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)

Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)

Diuretics

Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)

4.2 ATC Code

C - Cardiovascular system

C03 - Diuretics

C03B - Low-ceiling diuretics, excl. thiazides

C03BX - Other low-ceiling diuretics

C03BX03 - Cicletanine

API SUPPLIERS